Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.

C Genovese, Mark; D McKay, James; L Nasonov, Evgeny; F Mysler, Eduardo; A da Silva, Nilzio; Alecock, Emma; Woodworth, Thasia; J Gomez-Reino, Juan

doi:10.1002/art.23940

Public

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.

Published in Arthritis and rheumatism • Oct 1, 2008

NobleIDark:/48914/w1/20260526/4896A1B0Record on NobleID

Authors:

Mark C Genovese

,

James D McKay

,

Evgeny L Nasonov

Abstract

OBJECTIVE: To examine the efficacy and safety of the humanized anti-interleukin-6 receptor antibody tocilizumab combined with conventional disease-modifying antirheumatic drugs (DMARDs) in patients with active rheumatoid arthritis (RA). METHODS: A total of 1,220 patients were randomized (2:1 ratio) ...

Discussions